ArticleJournal of pharmaceutical innovation2022

Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022.

Isra DmourPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.